📚 Comprehensive Study Guide: Key Bacterial Pathogens

This study material provides a detailed overview of several critical bacterial pathogens. It is compiled from a lecture audio transcript and supplementary text from the "Sogno Digital Hub" document. The content is organized to enhance understanding of each microorganism's fundamental characteristics, disease mechanisms, identification methods, and strategies for treatment and prevention.

---

🦠 I. Enterococci

1. Taxonomy 📚

• Family: Enterococcaceae
• Genus: Enterococcus
• Important Species:
  • Enterococcus faecalis (most common)
  • Enterococcus faecium (often multidrug-resistant)
• Historical Note: Formerly classified as Group D streptococci.

2. Morphology 🔬

• Gram Stain: Gram-positive ovoid cocci.
• Arrangement: Occur in pairs or short chains.
• Spore Formation: Non-spore-forming.
• Appearance: May appear more "robust" than streptococci.

3. Physiology 🧪

• Oxygen Requirement: Facultative anaerobes.
• Catalase Test: Catalase-negative (sometimes a weak reaction).
• Growth Conditions:
  • Grow in 6.5% NaCl (important diagnostic test).
  • Bile-esculin positive (causes blackening of the medium).
  • Grow at a wide temperature range: 10–45°C.
• Survival: Can survive harsh conditions (disinfectants, drying).

4. Antigenic Structure 🛡️

• Cell Wall: Group D antigen (teichoic acid).
• Capsule: Present in some strains.
• Surface Adhesins: Aggregation substance.
• Toxins: Cytolysin in some Enterococcus faecalis strains.

5. Determinants of Pathogenicity 🦠

• Biofilm Formation: Crucial for colonization on catheters and prosthetic materials.
• Intrinsic Antibiotic Resistance: Naturally resistant to aminoglycosides and cephalosporins.
• Vancomycin Resistance: Acquisition of vanA and vanB genes leads to Vancomycin-Resistant Enterococci (VRE).
• Adhesion: Aggregation substance facilitates attachment to host cells.
• Tissue Damage: Gelatinase and cytolysin contribute to tissue destruction.

6. Ecology & Epidemiology 🌍

• Normal Flora: Part of the normal flora of the colon and genitourinary tract.
• Nosocomial Infections: A major cause of hospital-acquired infections.
• Transmission: Spread via hands and contaminated hospital surfaces.
• High-Risk Settings: Common in ICUs, catheterized patients, and individuals with prolonged hospitalization.

7. Clinical Syndromes 🤒

• Urinary Tract Infections (UTIs), especially catheter-associated.
• Bacteremia.
• Endocarditis.
• Wound infections.
• Intra-abdominal infections.
• Neonatal sepsis.

8. Immunity 💪

• Lasting Immunity: No lasting immunity after infection.
• Phagocytosis: Resistant to phagocytosis.
• Vaccine: No vaccine available.
• Serology: Not useful for diagnosis.

9. Microbiological Diagnosis 🔍

• A. Specimen Collection: Urine, blood, wound swabs, catheter tips, body fluids.
• B. Direct Microscopy: Gram-positive cocci in pairs/short chains; not distinctive enough alone.
• C. Culture:
  • Growth on blood agar (usually non-hemolytic or alpha-hemolytic).
  • Bile-Esculin agar: black colonies (positive).
  • 6.5% NaCl broth: growth (positive).
  • PYR test positive.
  • Must be separated from Group D Streptococcus bovis (PYR negative, no NaCl growth).
• D. Identification: Biochemical panels (API 20Strep, automated systems), MALDI-TOF, PCR for vancomycin-resistance genes (vanA, vanB).
• E. Antibiotic Susceptibility Testing (CRITICAL): Essential due to resistance. Determine susceptibility to ampicillin, vancomycin. Detect VRE (vanA/vanB). High-level gentamicin resistance testing for synergy decisions.

10. Treatment & Prevention 💊

• Treatment:
  • E. faecalis: Ampicillin + gentamicin (synergy).
  • E. faecium: Often resistant; vancomycin or linezolid.
  • VRE: Linezolid, daptomycin, tigecycline.
• Prevention: Hand hygiene, catheter care, hospital surface decontamination, isolation for VRE patients, antibiotic stewardship.

---

🦠 II. Corynebacterium diphtheriae

1. Taxonomy 📚

• Family: Corynebacteriaceae
• Genus: Corynebacterium
• Species: Corynebacterium diphtheriae
• Biotypes: gravis, mitis, intermedius, belfanti.
• Toxin Production: Only strains infected by β-phage produce diphtheria toxin.

2. Morphology 🔬

• Gram Stain: Gram-positive club-shaped rods (pleomorphic).
• Arrangement: "Chinese letter" or palisade arrangement.
• Special Features: Metachromatic granules (volutin granules) visible with Albert or Neisser stain.
• Motility/Spore: Non-motile, non-spore-forming.
• Appearance: Slender rods with swollen ends ("diphtheroid" appearance).

3. Physiology 🧪

• Oxygen Requirement: Aerobic.
• Catalase Test: Catalase-positive.
• Growth: Grows on simple and enriched media; optimum growth at 37°C.
• Metabolism: Ferments glucose and maltose.
• Culture: Produces black colonies on tellurite-containing media.
• Toxin Production: Occurs only in iron-limited conditions.

4. Antigenic Structure 🛡️

• Cell Wall: Arabinogalactan, meso-DAP.
• K Antigen: Somatic antigen.
• Diphtheria Toxin: A-B exotoxin.
  • Fragment B binds to host cell receptor.
  • Fragment A inhibits EF-2, stopping protein synthesis.
  • Toxin gene (tox) carried by β-phage.

5. Determinants of Pathogenicity 🦠

• Diphtheria Toxin: The primary virulence factor, causing systemic effects.
• Adhesion: Mechanisms for attachment to respiratory epithelium.
• Pseudomembrane Formation: Local tissue necrosis and inflammation leading to pseudomembrane.

6. Ecology & Epidemiology 🌍

• Reservoir: Humans are the only reservoir.
• Transmission: Droplets, direct contact.
• Carriers: Common.
• Risk Groups: Children and unvaccinated adults.
• Outbreaks: Occur where vaccination coverage is low.
• Prevention: Preventable with DTP/DTaP vaccine.

7. Clinical Syndromes 🤒

• Respiratory Diphtheria (Classic Form):
  • Sore throat, fever.
  • Gray-white pseudomembrane on tonsils/pharynx.
  • "Bull neck" (cervical lymphadenitis).
  • Potential airway obstruction.
  • Complications: myocarditis, polyneuritis.
• Cutaneous Diphtheria:
  • Chronic ulcers with gray membrane.
  • Less toxin absorption.

8. Immunity 💪

• Antitoxin: Natural infection does NOT guarantee long-lasting immunity.
• Vaccination: Induces strong protective antitoxin (IgG) that neutralizes diphtheria toxin.
• Measurement: Immunity historically measured with Schick test.

9. Microbiological Diagnosis 🔍

• ⚠️ Medical Emergency: Diagnosis and treatment must start simultaneously.
• A. Specimen Collection: Throat swab (from pseudomembrane edge), nasopharyngeal swab, swabs from skin lesions. Use appropriate transport media (e.g., Amies).
• B. Direct Microscopy:
  • Gram stain: Gram-positive club-shaped rods, irregular arrangement ("Chinese letters").
  • Special stains (Albert / Neisser stain): Show blue/black metachromatic granules; very helpful for rapid presumptive diagnosis.
• C. Culture:
  • Selective media: Löffler’s serum medium (enhances granule formation, good for early ID), Tellurite-containing media (Tinsdale agar → black colonies with brown halo; Potassium tellurite agar → gray to black colonies).
  • Blood agar: Small colonies; morphology varies by biotype (gravis → large gray; mitis → small black; intermedius → intermediate).
• D. Identification: Gram-positive bacilli, catalase-positive, sugar fermentation profile (glucose, maltose), urease test for species differentiation.
• E. Toxin Production Testing (CRUCIAL): Diagnosis is complete only with toxin confirmation.
  • Elek Test (Immunodiffusion): Gold standard. Filter paper strip with antitoxin on agar; toxigenic strains produce visible precipitation lines.
  • PCR: Detects tox gene; fast, highly specific, increasingly used.
  • ELISA: Detects diphtheria toxin in clinical samples; less common but useful.
• F. Additional Lab Findings: Leukocytosis, elevated cardiac enzymes (if myocarditis). Culture + toxin testing required for public health notification.

10. Treatment & Prevention 💊

• Treatment:
  1. Diphtheria antitoxin: MUST be given immediately on suspicion (neutralizes toxin).
  2. Antibiotics: Erythromycin or penicillin (eliminates bacteria, stops transmission).
  3. Supportive Care: Airway management (if obstruction), cardiac monitoring (for myocarditis).
• Prevention: DTaP / Tdap vaccines (contain diphtheria toxoid), booster every 10 years, isolation of cases, prophylactic antibiotics for close contacts, vaccination of contacts if not immune.

---

🦠 III. Clostridium perfringens

1. Taxonomy 📚

• Family: Clostridiaceae
• Genus: Clostridium
• Species: Clostridium perfringens
• Types: A–E based on toxin production (Type A most common in human disease).

2. Morphology 🔬

• Gram Stain: Large Gram-positive rods ("boxcar-shaped").
• Motility: Non-motile (important distinguishing feature).
• Spore Formation: Spore-forming, but spores rarely seen in tissue.
• Capsule: Present in some strains.
• Arrangement: Occur singly or in pairs.
• Shape: Straight-edged rods with blunt ends.

3. Physiology 🧪

• Oxygen Requirement: Obligate anaerobe (but aerotolerant).
• Growth Rate: Rapid growth (doubling time ~8–10 min).
• Metabolism: Ferments carbohydrates → gas production.
• Toxins/Enzymes: Produces numerous enzymes and toxins.
• Culture: Grows on simple media; characteristic double zone of hemolysis on blood agar.

4. Antigenic Structure 🛡️

• α-toxin: Phospholipase C / lecithinase (MAJOR toxin).
• Other Toxins: θ-toxin, κ-toxin, µ-toxin, ν-toxin (various tissue-destructive enzymes).
• Enterotoxin (CPE): Responsible for food poisoning.
• Antigens: Heat-labile and heat-stable antigens.

5. Determinants of Pathogenicity 🦠

• α-toxin (Lecithinase): Destroys cell membranes, causing myonecrosis.
• Gas Production: Leads to crepitus and tissue separation.
• Enzymes: Collagenase, hyaluronidase facilitate tissue spread.
• Enterotoxin: Affects GI tract, causing food poisoning.
• Rapid Multiplication: Overwhelms host defenses.
• Spore Survival: Spores survive in soil and environment.

6. Ecology & Epidemiology 🌍

• Found in: Soil, dust, intestines of humans & animals.
• Causes: Gas gangrene (clostridial myonecrosis), anaerobic cellulitis, food poisoning.
• Associated with: Traumatic wounds, compound fractures, surgical wounds, abortions.
• Food Poisoning: Linked to meat dishes left at room temperature.

7. Clinical Syndromes 🤒

• 1. Gas Gangrene (Clostridial Myonecrosis): Severe muscle pain, edema, crepitus (gas), black necrotic tissue, foul discharge, severe systemic toxemia → shock.
• 2. Anaerobic Cellulitis: Less severe, localized gas formation.
• 3. Food Poisoning: Watery diarrhea, abdominal cramps, no fever, self-limiting (8–24 hours).
• 4. Necrotizing Enteritis (Pig-bel): Rare.

8. Immunity 💪

• Natural Immunity: Poor.
• Antibodies: Antitoxin antibodies may form but are not protective.
• Vaccine: No vaccine for general population.
• Antitoxin: Only used therapeutically in some cases.

9. Microbiological Diagnosis 🔍

• A. Specimen Collection: Wound tissue, aspirates (BEST specimen), blood culture (sepsis), stool (for food poisoning, toxin detection). Avoid swabs (low yield).
• B. Direct Microscopy:
  • Gram stain: Large Gram-positive rods, boxcar-shaped. Few WBCs (toxins destroy neutrophils) → important clue. Spores rarely visible.
  • "Stormy fermentation" in milk medium: Curds disrupted by gas → classic laboratory test.
• C. Culture (Gold Standard):
  • Media: Blood agar under anaerobic conditions (double zone of hemolysis: inner = complete, outer = partial), Egg yolk agar (lecithinase positive → opalescent halo), Thioglycollate broth (for anaerobic growth).
  • Nagler Reaction: Antitoxin neutralizes α-toxin, inhibiting lecithinase halo.
  • Colony morphology: Large, irregular colonies, "ground-glass" appearance, gas bubbles.
• D. Biochemical Tests: Non-motile, lecithinase positive (crucial), lactose fermentation variable, H₂S positive, rapid growth.
• E. Toxin Detection: ELISA or latex tests (detect enterotoxin in stool), PCR (detects genes for α-toxin (plc), enterotoxin (cpe)), bioassay (historical).
• F. Imaging/Clinical Clues: Gas in tissues on X-ray or CT; sudden onset severe pain + gas → high suspicion.

10. Treatment & Prevention 💊

• Treatment:
  • Life-threatening infections (gas gangrene): Surgical debridement (urgent), high-dose penicillin G, clindamycin (to inhibit toxin synthesis), broad anaerobic coverage (if polymicrobial), hyperbaric oxygen therapy (adjunct).
  • Food poisoning: Supportive therapy only; no antibiotics needed.
• Prevention: Proper wound cleaning, prophylactic antibiotics in major trauma, food handling hygiene, adequate cooking & refrigeration of meat, avoid contamination of surgical wounds.

---

🦠 IV. Mycobacterium tuberculosis

1. Taxonomy 📚

• Family: Mycobacteriaceae
• Genus: Mycobacterium
• Species: Mycobacterium tuberculosis
• Disease: Tuberculosis (TB).

2. Morphology 🔬

• Gram Stain: Weakly Gram-positive (often appears Gram-neutral or "ghost" cells).
• Acid-Fast Stain: Acid-fast bacilli (AFB) due to mycolic acid in cell wall.
• Shape: Slender, slightly curved rods.
• Spore/Motility: Non-motile, non-spore-forming.

3. Physiology 🧪

• Oxygen Requirement: Obligate aerobe.
• Growth Rate: Very slow growth (doubling time 15-20 hours).
• Culture: Requires special media; optimum growth at 37°C.
• Mycolic Acid: Waxy cell wall makes it resistant to drying, disinfectants, and many antibiotics.
• Catalase: Heat-labile catalase positive.
• Niacin: Niacin accumulation positive.

4. Antigenic Structure 🛡️

• Cell Wall: Rich in mycolic acids, complex lipids, glycolipids, and peptidoglycan.
• Antigens: Lipoarabinomannan (LAM), ESAT-6, CFP-10 (important for immune response and diagnosis).
• Weak Antigenicity: Contributes to chronic disease.

5. Determinants of Pathogenicity 🦠

• Intracellular Survival: Survives and multiplies within macrophages.
• Cord Factor: Inhibits phagosome-lysosome fusion, toxic to host cells.
• Sulfatides: Inhibit phagosome-lysosome fusion.
• Mycolic Acid: Protects from host defenses and desiccation.
• Granuloma Formation: Host immune response forms granulomas (tubercles) to contain infection, but can also lead to tissue damage.

6. Ecology & Epidemiology 🌍

• Reservoir: Humans are the primary reservoir.
• Transmission: Airborne droplets (coughing, sneezing).
• Risk Factors: Immunosuppression (HIV), malnutrition, crowded living conditions, poverty, diabetes, substance abuse.
• Global Impact: Major global health problem, especially in developing countries.

7. Clinical Syndromes 🤒

• Primary TB: Initial infection, often asymptomatic or mild flu-like symptoms. May progress to active disease or latent infection.
• Latent TB Infection (LTBI): Asymptomatic, non-infectious, but positive TST/IGRA. Risk of reactivation.
• Active TB Disease:
  • Pulmonary TB (most common): Chronic cough (often with blood-streaked sputum), fever, night sweats, weight loss, fatigue.
  • Extrapulmonary TB: Affects lymph nodes, pleura, bones, joints, kidneys, CNS (meningitis), miliary TB (disseminated).

8. Immunity 💪

• Cell-Mediated Immunity (CMI): Primary protective mechanism (Th1 response).
• Antibodies: Humoral immunity plays a minor role.
• Partial Immunity: Natural infection provides partial, but not complete, protection.
• Vaccine: BCG vaccine offers partial protection, especially against severe forms in children.

9. Microbiological Diagnosis 🔍

• A. Specimen Collection: Sputum (3 early-morning samples), BAL, gastric aspirate (children), CSF, urine, pleural fluid, tissue biopsy.
• B. Direct Microscopy:
  • Ziehl–Neelsen stain (ZN): Red, beaded, acid-fast bacilli. Moderate sensitivity, useful for rapid screening.
  • Auramine-rhodamine fluorescent stain: More sensitive than ZN.
• C. Culture (GOLD STANDARD):
  • Media: Lowenstein–Jensen (LJ) medium (egg-based), Middlebrook 7H10/7H11 agar, automated liquid culture (MGIT for fast detection).
  • Characteristics: Slow growth (3–8 weeks), rough buff colonies ("cauliflower"), niacin accumulation positive, heat-labile catalase positive.
• D. Molecular Tests:
  • GeneXpert MTB/RIF: Rapid (2 hours), detects TB DNA + rifampicin resistance. WHO recommended.
  • PCR for IS6110: High sensitivity.
  • Line probe assays: Detect MDR-TB resistance genes.
• E. Immunological Tests:
  • Tuberculin Skin Test (TST/Mantoux): Detects delayed hypersensitivity. Positive in infection or BCG vaccination.
  • IGRA (Interferon-Gamma Release Assay): Uses ESAT-6, CFP-10 antigens. Not affected by BCG.
• F. Other Tests: Chest X-ray (widened mediastinum, infiltrates), histology (caseating granulomas), ESR elevated, ADA in pleural fluid ↑ (supportive).

10. Treatment & Prevention 💊

• Treatment (RIPE regimen):
  • Rifampicin
  • Isoniazid
  • Pyrazinamide
  • Ethambutol
  • Duration: 6 months.
  • MDR-TB: Fluoroquinolones + injectables.
• Prevention: BCG vaccine, early detection, isolation, masks, ventilation, screening of contacts.

---

🦠 V. Mycobacterium leprae

1. Taxonomy 📚

• Family: Mycobacteriaceae
• Genus: Mycobacterium
• Species: Mycobacterium leprae
• Disease: Leprosy (Hansen’s disease).
• Nature: Obligate intracellular acid-fast bacillus.

2. Morphology 🔬

• Shape: Slender, slightly curved rods, 1–8 µm.
• Acid-Fast Stain: Strongly acid-fast (Fite-Faraco stain best).
• Motility/Spore/Capsule: Non-motile, non-spore-forming, non-capsulated.
• Arrangement: Often seen in clusters (globi) inside macrophages (especially in lepromatous type), parallel bundles ("cigar-shaped").

3. Physiology 🧪

• Oxygen Requirement: Obligate intracellular pathogen.
• Culture: Cannot grow on artificial media. Grows only in mouse footpads and armadillos.
• Growth Rate: Very slow growth (doubling time 14 days).
• Temperature: Optimal temperature 27–33°C, explaining predilection for cooler body areas (skin, peripheral nerves, nose, ears, extremities).

4. Antigenic Structure 🛡️

• Surface Antigen: Phenolic glycolipid-1 (PGL-1) – major surface antigen, used in serology.
• Immune Modulator: Lipoarabinomannan (LAM).
• Cell Wall: Mycolic acids, complex lipids, glycolipids.
• Antigenicity: Weak antigenicity contributes to chronic disease.

5. Determinants of Pathogenicity 🦠

• Nerve Damage: PGL-1 binds to Schwann cells, leading to nerve damage.
• Intracellular Survival: Inhibits macrophage killing.
• Immune Evasion: Weak stimulation of Th1 response.
• Clinical Manifestations: Ability to cause sensory nerve destruction, skin infiltration, deformities in advanced disease.
• Chronic Granulomatous Inflammation: Characteristic of the disease.

6. Ecology & Epidemiology 🌍

• Reservoir: Humans are the primary reservoir. Secondary reservoirs: armadillos (USA), monkeys.
• Transmission: Prolonged close contact, respiratory droplets (nasal secretions). Skin contact less common.
• Incubation Period: Long, 3–20 years.
• Endemic Areas: India, Nepal, Brazil, SE Asia, Africa.

7. Clinical Syndromes 🤒

• Two Polar Forms (Ridley–Jopling Classification):
  • 1. Tuberculoid Leprosy (TT): Strong cell-mediated immunity, few anesthetic skin lesions (hypopigmented), nerve thickening, few or absent AFB, granulomatous inflammation.
  • 2. Lepromatous Leprosy (LL): Weak immunity, numerous symmetric skin lesions (nodules, plaques, diffuse infiltration), many AFB in lesions (globi), leonine facies (facial thickening), nasal perforation, eyebrow loss, high infectiousness.
• Intermediate Forms: BT, BB, BL.
• Complications: Sensory loss → burns, ulcers; deformities of hands/feet; reactional states (Type 1 and Type 2 ENL).

8. Immunity 💪

• Cell-Mediated Immunity (Th1): Determines disease form. Strong Th1 → tuberculoid (few bacilli); Weak Th1 → lepromatous (many bacilli).
• Humoral Immunity: Humoral antibodies are present but not protective.
• Delayed-Type Hypersensitivity: Positive lepromin test (TT).

9. Microbiological Diagnosis 🔍

• A. Specimens: Skin smears, skin biopsy, nasal scrapings, nerve biopsy (special cases).
• B. Microscopy:
  • Fite–Faraco stain: Acid-fast bacilli seen (many in LL, few/none in TT).
  • Bacteriological Index (BI): Used to grade bacillary load.
• C. Histopathology: LL: foamy macrophages (Virchow cells) filled with AFB; TT: well-formed granulomas.
• D. Molecular: PCR for M. leprae DNA (gene probes with M. leprae–specific sequences).
• E. Serology: Anti-PGL-1 antibodies (ELISA) – 95% sensitivity for LL, 30% for TT.
• F. Lepromin (Mitsuda) Test: NOT diagnostic. Used to determine host immunity (supportive for TT). Not available in the US.

10. Treatment & Prevention 💊

• Treatment (WHO MDT – Multi-Drug Therapy):
  • Tuberculoid (Paucibacillary): Rifampicin + Dapsone for 6 months.
  • Lepromatous (Multibacillary): Rifampicin + Dapsone + Clofazimine for 12–24 months.
• Prevention: Early detection and treatment of cases, BCG vaccine offers partial protection, prophylaxis for contacts (single-dose rifampicin), avoid prolonged contact with untreated patients.

---

🦠 VI. Bordetella pertussis

1. Taxonomy 📚

• Family: Alcaligenaceae
• Genus: Bordetella
• Species: Bordetella pertussis (primary agent of whooping cough).
• Other Species: B. parapertussis (milder disease), B. bronchiseptica (animal pathogen, rare in humans).

2. Morphology 🔬

• Gram Stain: Small Gram-negative coccobacilli.
• Arrangement: Appear singly or in pairs.
• Motility: Non-motile.
• Capsule: Encapsulated.
• Survival: Delicate organisms, killed easily outside host.

3. Physiology 🧪

• Oxygen Requirement: Strict aerobes.
• Growth: Very fastidious, require special enriched media (e.g., Bordet-Gengou, Regan-Lowe). Slow growth (3–7 days).
• Metabolism: Do NOT ferment carbohydrates.
• Enzymes: Oxidase-positive, catalase-positive.
• Sensitivity: Sensitive to drying, sunlight, and fatty acids.

4. Antigenic Structure 🛡️

• Endotoxin: Lipooligosaccharide (LOS).
• Major Virulence Factor: Pertussis toxin (PT).
• Adhesins: Filamentous hemagglutinin (FHA), Fimbriae.
• Other Toxins: Adenylate cyclase toxin, Tracheal cytotoxin.

5. Determinants of Pathogenicity 🦠

• Attachment: Adheres to ciliated epithelial cells via FHA, PT, fimbriae.
• Ciliary Damage: Immobilization and destruction of cilia → persistent cough.
• Immune Evasion: Various mechanisms.
• Pertussis Toxin: Causes lymphocytosis, hypoglycemia.
• Adenylate Cyclase Toxin: Inhibits phagocytes (neutrophils).
• Tracheal Cytotoxin: Causes ciliostasis and necrosis.
• Endotoxin (LOS): Contributes to inflammation.
• Invasion: No invasion; disease due to toxins.

6. Ecology & Epidemiology 🌍

• Reservoir: Humans are the only reservoir.
• Transmission: Respiratory droplets.
• Contagiousness: Highly contagious (attack rate >90%).
• Risk Groups: Most severe in infants <6 months. Adolescents & adults are carriers and reservoirs.
• Outbreaks: Occur every 3–5 years.
• Prevention: Mainly through vaccination (DTaP/Tdap).

7. Clinical Syndromes 🤒

• Whooping Cough (Pertussis) – 3 Stages:
  • 1. Catarrhal Stage (1–2 weeks): Rhinorrhea, mild cough. Highly contagious. Best time to isolate organism.
  • 2. Paroxysmal Stage (2–6 weeks): Severe paroxysms of coughing, inspiratory "whoop," post-tussive vomiting, lymphocytosis.
  • 3. Convalescent Stage (weeks–months): Gradual recovery.
• Complications: Pneumonia, seizures, encephalopathy, apnea in infants.

8. Immunity 💪

• Natural Infection: Induces immunity, but it wanes.
• Vaccines: Acellular DTaP/Tdap vaccines induce protective antibodies (target PT, FHA, pertactin, fimbriae).
• Lifelong Immunity: No lifelong immunity → boosters required.

9. Microbiological Diagnosis 🔍

• A. Specimen Collection (Most Important): Nasopharyngeal aspirate (BEST), nasopharyngeal swab. Use calcium alginate or Dacron swabs (cotton inhibits growth). Collect during catarrhal stage for highest yield.
• B. Direct Microscopy:
  • Gram stain: Not very useful (tiny G-negative coccobacilli).
  • Direct Immunofluorescence (DFA): Rapid but low specificity; used for screening only.
• C. Culture (Gold Standard): Sensitivity drops after 2 weeks of illness.
  • Media: Bordet–Gengou agar (potato-blood-glycerol), Regan–Lowe charcoal agar (transport + culture medium).
  • Colony characteristics: Appear in 3–7 days, small, smooth, glistening, "mercury drop" colonies. Requires fresh media.
• D. Molecular Diagnosis (Preferred Today):
  • PCR: Most sensitive & rapid. Detects DNA of B. pertussis. Can distinguish B. pertussis vs B. parapertussis. Useful when culture is negative (late stages).
• E. Serology: Used in late disease (after 3 weeks) when culture/PCR are negative. ELISA for IgG anti-pertussis toxin (PT). Fourfold rise in paired sera is diagnostic.
• F. Additional Lab Findings: Marked lymphocytosis (due to pertussis toxin), chest X-ray (perihilar infiltrates, supportive).

10. Treatment & Prevention 💊

• Treatment:
  • Antibiotics: Macrolides (azithromycin, clarithromycin, erythromycin). Early therapy reduces transmission.
  • Supportive Treatment: Oxygen, suctioning.
• Prophylaxis: Macrolides for all close contacts.
• Prevention:
  • Vaccination: DTaP (children), Tdap booster (adolescents, adults, pregnant women). Prevents severe disease but immunity wanes.
  • Isolation: Of patient (5 days after antibiotics).

---

🦠 VII. Shigella spp.

1. Taxonomy 📚

• Family: Enterobacteriaceae
• Genus: Shigella
• Species (Groups):
  • Group A: S. dysenteriae
  • Group B: S. flexneri
  • Group C: S. boydii
  • Group D: S. sonnei
• Characteristics: All are non-motile, Gram-negative rods associated with bacillary dysentery.

2. Morphology 🔬

• Gram Stain: Gram-negative short rods.
• Motility: Non-motile (key differentiating point).
• Spore Formation: Non-spore-forming.
• Appearance: May show bipolar staining ("safety-pin appearance").
• Flagella: No flagella.
• Capsule: Usually absent (except some S. sonnei).

3. Physiology 🧪

• Oxygen Requirement: Facultative anaerobes.
• Lactose Fermentation: Non-lactose fermenting on MacConkey agar (pale colonies; S. sonnei may be late-lactose fermenter).
• Catalase Test: Catalase-positive (except S. dysenteriae type 1).
• H₂S Production: Do not produce H₂S (distinguishes from Salmonella).
• Oxidase Test: Oxidase-negative.
• Metabolism: Acid from glucose without gas.
• Survival: Survive acidic environment → low infectious dose.

4. Antigenic Structure 🛡️

• O Antigen: Somatic antigen (LPS) → basis of serogroups.
• H Antigen: No H antigen (non-motile).
• Shiga Toxin: Some strains produce Shiga toxin (especially S. dysenteriae type 1).

5. Determinants of Pathogenicity 🦠

• Invasion Plasmid Antigens (Ipa proteins): Essential for epithelial cell invasion.
• Type III Secretion System: Injects virulence proteins into host cells.
• Shiga Toxin (Stx): (Produced by S. dysenteriae 1). Inhibits 60S ribosomal subunit → cell death. Causes severe colitis & HUS.
• Intracellular Spread: Uses actin polymerization.
• LPS Endotoxin: Contributes to inflammation.

6. Ecology & Epidemiology 🌍

• Reservoir: Human is the only reservoir.
• Transmission: Fecal–oral, contaminated food/water, person-to-person.
• Infectious Dose: Very low (10–100 organisms) → outbreaks common.
• Risk Groups: Affects mainly children, crowded institutions, endemic in developing countries.
• Species Distribution: S. sonnei – common in industrialized countries; S. dysenteriae – severe epidemics.

7. Clinical Syndromes 🤒

• Shigellosis (Bacillary Dysentery):
  • Acute onset fever, abdominal cramps, tenesmus.
  • Watery diarrhea → later bloody, mucous stools.
  • Severe dehydration possible.
• Complications: HUS (Shiga toxin), toxic megacolon, sepsis (rare).

8. …